RxDoctor Payments DataLook up a doctor →

Davida Kruger, APRN

Nurse Practitioner · Detroit, MINPI 1497897961

Payments from drug & device makers

$1,765,889in general payments, 2019–2025

Across 1,133 payments — averaging $1558.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$415K
  • Abbott$316K
  • Sequel Med Tech, LLC$250K
  • Novo Nordisk$210K
  • Dexcom, Inc.$200K
  • Insulet Corporation$184K
  • plus $191K from 11 others

What the payments were for

  • Consulting fees$167,89723%
  • Speaking & faculty fees$478,57265%
  • Travel & lodging$76,13510%
  • Food & beverage$15,8942%
  • Education$1600%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,765,889 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$10,402
Medicare patients
40
Services billed
169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$168,883
JardianceEmpagliflozin47$67,918
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/737$53,855
TrulicityDulaglutide18$32,963
NovologInsulin Aspart75$29,690
MounjaroTirzepatide24$25,803
Novolog FlexpenInsulin Aspart40$14,736
HumalogInsulin Lispro27$12,976
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$12,840
Tresiba Flextouch U-200Insulin Degludec13$10,941
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$10,850
Tresiba Flextouch U-100Insulin Degludec11$10,434
Gvoke Hypopen 2-PackGlucagon13$10,136
Humalog Kwikpen U-100Insulin Lispro20$8,873
Admelog SolostarInsulin Lispro13$5,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$209,877$198,573164 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$97,978$71,74269 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →